Prothena Corporation PLC (NASDAQ:PRTA)‘s stock had its “buy” rating restated by analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Thursday. They presently have a $70.00 price objective on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price target would indicate a potential upside of 23.61% from the stock’s previous close.

Several other equities research analysts have also recently commented on the stock. Deutsche Bank AG set a $73.00 price objective on shares of Prothena Corporation PLC and gave the company a “buy” rating in a research report on Monday, October 23rd. ValuEngine cut shares of Prothena Corporation PLC from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Prothena Corporation PLC in a research report on Monday, October 2nd. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Prothena Corporation PLC in a research report on Monday, October 2nd. Finally, Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corporation PLC in a research report on Friday, September 29th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. Prothena Corporation PLC currently has a consensus rating of “Buy” and an average target price of $78.58.

Prothena Corporation PLC (NASDAQ PRTA) opened at $56.63 on Thursday. Prothena Corporation PLC has a 52-week low of $45.13 and a 52-week high of $70.00.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.37) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.04. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.28 million. Prothena Corporation PLC had a negative net margin of 562.19% and a negative return on equity of 34.40%. The firm’s revenue was down 33.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.26) EPS. research analysts predict that Prothena Corporation PLC will post -4.41 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/11/prothena-corporation-plc-prta-rating-reiterated-by-oppenheimer-holdings-inc.html.

In other Prothena Corporation PLC news, Director Christopher S. Henney sold 900 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $70.00, for a total transaction of $63,000.00. Following the sale, the director now directly owns 900 shares of the company’s stock, valued at approximately $63,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tara Nickerson sold 17,500 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the sale, the insider now directly owns 19,500 shares in the company, valued at $1,240,200. The disclosure for this sale can be found here. Insiders have sold a total of 29,424 shares of company stock worth $1,922,787 over the last three months. Insiders own 3.10% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Legal & General Group Plc lifted its position in Prothena Corporation PLC by 15.0% during the 3rd quarter. Legal & General Group Plc now owns 15,761 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 2,053 shares in the last quarter. American International Group Inc. increased its stake in shares of Prothena Corporation PLC by 8.1% during the 3rd quarter. American International Group Inc. now owns 25,746 shares of the biotechnology company’s stock worth $1,668,000 after purchasing an additional 1,925 shares during the last quarter. Sphera Funds Management LTD. increased its stake in shares of Prothena Corporation PLC by 50.0% during the 3rd quarter. Sphera Funds Management LTD. now owns 60,000 shares of the biotechnology company’s stock worth $3,886,000 after purchasing an additional 20,000 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Prothena Corporation PLC by 70.8% during the 3rd quarter. SG Americas Securities LLC now owns 6,942 shares of the biotechnology company’s stock worth $450,000 after purchasing an additional 2,878 shares during the last quarter. Finally, Hood River Capital Management LLC increased its stake in shares of Prothena Corporation PLC by 2.2% during the 3rd quarter. Hood River Capital Management LLC now owns 198,276 shares of the biotechnology company’s stock worth $12,842,000 after purchasing an additional 4,202 shares during the last quarter.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.